Press coverage about Mirna Therapeutics (NASDAQ:SYBX) has trended positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mirna Therapeutics earned a daily sentiment score of 0.26 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.9909550530241 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Synlogic Reports Third Quarter 2017 Financial Results and Recent Progress (finance.yahoo.com)
- Latin America Multiple Myeloma Therapeutics Market Competitive Landscape By 2021 (reports.pr-inside.com)
- New Peer Reviewed Publication Shows That BrainStorm’s NurOwn® Has a Unique miRNA Signature (markets.businessinsider.com)
- Synlogic Reports Positive Top-Line Phase 1 Data Demonstrating Safety and Tolerability and Proof of Mechanism in Healthy Volunteers for SYNB1020, a Synthetic BioticTM Medicine for the Treatment of Hyperammonemia (finance.yahoo.com)
- Synlogic to Present at Upcoming Investor Conferences in November (finance.yahoo.com)
Shares of Mirna Therapeutics (SYBX) traded down $1.10 during trading on Tuesday, hitting $10.00. The company had a trading volume of 24,300 shares, compared to its average volume of 11,309. Mirna Therapeutics has a 1 year low of $8.05 and a 1 year high of $23.00.
Several research analysts recently issued reports on the company. ValuEngine downgraded Mirna Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Leerink Swann assumed coverage on Mirna Therapeutics in a research report on Tuesday, September 19th. They set an “outperform” rating and a $25.00 price objective for the company.
ILLEGAL ACTIVITY NOTICE: “Positive Media Coverage Somewhat Unlikely to Affect Mirna Therapeutics (SYBX) Share Price” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://transcriptdaily.com/2017/11/14/positive-media-coverage-somewhat-unlikely-to-affect-mirna-therapeutics-sybx-share-price.html.
Mirna Therapeutics Company Profile
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.